INmune Bio files for $250M mixed shelf offering

on MSN ago, source:

INmune Bio (NASDAQ:INMB) on Wednesday filed a prospectus for a mixed shelf offering of up to $250 million. This prospectus is ...

INmune Bio Independent Director Acquires 80% More Stock

7d ago, source:

Potential INmune Bio, Inc. ( NASDAQ:INMB) shareholders may wish to note that the Independent Director, Scott Juda, recently ...

INmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcript

1mon ago, source: InvestingChannel on MSN

INmune Bio, Inc. beats earnings expectations. Reported EPS is $-0.47, expectations were $-0.58. INMB isn't one of the 30 most ...

INmune Bio Inc INMB

3d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

8d ago, source:

The net proceeds is expected to fund the Company through the readout of the ongoing Phase 2 trial (AD02) in patients with Early Alzheimer’s Disease (AD) using XPro™ and through the metastatic ...

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

25d ago, source: Business Insider

INB03 decreased blood biomarkers of inflammation in patients with advanced cancer. About INmune Bio, Inc. INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company ...

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct ...

12d ago, source: The Bakersfield Californian

Boca Raton, Florida, April 22, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s ...

INmune Bio: An Opportunity In The Freefall (Rating Upgrade)

11d ago, source:

INmune Bio is focused on developing drugs for neurology and cancer medicine. Find out why INMB stock is a Buy.

INmune Bio Inc (INMB) Stock: Analyzing the Market Value

11d ago, source: newsheater

In conclusion, INmune Bio Inc (INMB) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note ...

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and ...

10d ago, source: The Bakersfield Californian

INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune ...

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024

25d ago, source: Nasdaq

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Sign up for our newsletter to get the latest on ...